nivolumab
Opdivo medication guide
Opdivo -- Indicated for resistant cases of melanoma and NSCLC, given IV every 2 weeks. Defer to outpatient setting if possible. Rare inpatient use expected.
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Reviewed: 25 August 2015 (Opdivo)
Opdivo medication guide
Opdivo -- Indicated for resistant cases of melanoma and NSCLC, given IV every 2 weeks. Defer to outpatient setting if possible. Rare inpatient use expected.
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Reviewed: 25 August 2015 (Opdivo)